ART1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the A-549 lung adenocarcinoma cell line, featuring disruption of the ART1 gene. This heterogeneous knockout pool eliminates functional ART1 protein, establishing a loss-of-function model for studying ART1-mediated processes without clonal selection bias. The polyclonal preparation is suited for robust functional investigations of ART1??s roles in signaling, adhesion, and immune modulation in non-small cell lung cancer.
The A-549 cell line, derived from a 58-year-old Caucasian male lung adenocarcinoma, is a widely used model for human non-small cell lung carcinoma. It retains features of type II alveolar pneumocytes, such as surfactant protein expression and lamellar body formation, rendering it valuable for investigating epithelial tumorigenesis, metastatic progression, and pharmacological interventions. The cells?? established genetic background and well-documented growth characteristics make them an ideal host for CRISPR/Cas9-based gene disruption studies.
ART1 encodes a GPI-anchored ADP-ribosyltransferase that transfers ADP-ribose from NAD? to cell surface proteins, including integrin ??7 and P2X7 receptor. This modification is stimulated by IFN-??, TNF-??, and Toll-like receptor ligands and alters protein function in adhesion, migration, and immune signaling. Downstream, ART1 impacts Src kinases, FAK, and NLRP3 inflammasome assembly, partly through interactions with CD38 in lipid rafts. Thus, ART1-driven ADP-ribosylation coordinates integrin-mediated cellular attachment and motility as well as purinergic inflammatory responses, influencing tumor-immune crosstalk.
In the A-549 lung adenocarcinoma system, knockout of ART1 disrupts this regulatory network, providing a model to examine the functional consequences on tumor cell?Cimmune interactions and metastatic potential. The loss of ART1 is expected to impair the ADP-ribosylation-dependent modulation of integrin ??7, altering cell adhesion and migration dynamics. Additionally, it may attenuate P2X7 receptor signaling, thereby reducing NLRP3 inflammasome activation and associated cytokine release. These changes can simulate a condition of reduced immune evasion, making the knockout cells a valuable tool for studying how lung carcinoma cells escape immune surveillance and for testing therapeutic strategies that target the ART1 pathway.
Researchers can employ the ART1 Knockout A-549 Polyclonal Cells in a broad range of experimental workflows, including comparative Western blot and RT-qPCR analyses to confirm target gene disruption, adhesion and migration assays to assess phenotypic changes, flow cytometry for surface receptor profiling, and cytokine ELISA to quantify inflammatory mediators. The model further supports drug sensitivity screening to identify compounds with enhanced efficacy in the ART1-deficient state and aids in the validation of immunotherapy targets directed against ADP-ribosylation pathways. For additional technical details or custom inquiries, please contact Ascent Research.
